The number of symptomatic hepatitis A cases has progressively been increasing during the last several years in Korea. Available cost estimates indicate a growing burden to the public. The purpose of this study was to determine the extent of treatment costs for patients with hepatitis A and to analyze the influential factors with nationwide data. We collected data on 72,921 patients with hepatitis A from 5-year National Health Insurance claim archives between 2004 and 2008. Multiple regression analyses were conducted to examine influential factors affecting treatment costs for hepatitis A. Total treatment costs for patients with hepatitis A during the 5-year period were US$47,902,087 and increased significantly each year. In total, 91.4% of treatment costs were used for hospitalization, and the proportion of inpatients increased gradually throughout the study period. The most influential factor on treatment costs was treatment duration. Our results show that the soaring number of patients with hepatitis A followed by the hospitalization-focused treatment practice is a major factor associated with the rapid increase in treatment costs. Appropriate policies should be promptly developed to control treatment costs and economic burden of hepatitis A infections.
Hepatitis A virus (HAV) infection has decreased substantially in developed countries during recent decades (Shapiro and Margolis 1993) , and outbreaks rarely occur (World Health Organization 2000) . In Korea, attention to hepatitis A was very low before the 1980s, because almost all citizens had hepatitis A antibodies and most of hepatitis A infections were asymptomatic (Hong and Kim 1982) . However, people had fewer opportunities to have anti-HAV antibodies through natural infection during childhood with improving sanitation and living standards. Young people in their teens or twenties showed less than 10% of anti-HAV positivity in 1995 (Roh et al. 1997) . So, the number of adult cases of hepatitis A has progressively increased.
Sporadic occurrences of the disease were reported in the 1980s until the mid-1990s and gradually spread throughout the country around 1997 (Sohn et al. 2000; Jung and Kim 2009 ). Since 2000, the reported number of patients with hepatitis A has been increasing and some outbreaks have been reported. Accordingly, the government declared hepatitis A as a notifiable infectious disease in 2000 and developed a sentinel surveillance system to identify hepatitis A outbreaks and to develop a proper disease management strategy. The number of patients with symptomatic hepatitis A reported to the Korea Centers for Disease Control and Prevention (KCDC) has grown explosively; 317 cases were reported in 2002 , 355 cases in 2004 , 2,081 cases in 2006 , 7,895 cases in 2008 , and 15,231 cases in 2009 (KCDC 2011 . Therefore, the recent rapid increase in the number of patients with hepatitis A in Korea has drawn considerable public attention.
Once a hepatitis A outbreak begins, many people are unpredictably influenced directly and indirectly, resulting in a substantial medical and economic burden. An outbreak can paralyze social functioning due to restrictions placed on general social activities, including school and work. Additionally, direct costs for the disease are high, and the economic cost of social recovery at the end of an outbreak is significant (Luyten and Beutels 2009) . Reliable analyses of treatment costs or economic burden are necessary to develop an appropriate disease management strategy for hepatitis A. Although studies analyzing the economic burden or the treatment costs for hepatitis A have been conducted in some developed countries (Dalton et al. 1996; Demicheli et al. 1996; Lucioni et al. 1998; Bownds et al. 2003; Sansom et al. 2003; Artega et al. 2009 ), most are not representative, because they used partial data from specific locations or medical institutions rather than nationwide data. Moreover, those studies conducted a limited analysis of medical service utilization and treatment costs associated with the characteristics of patients. Our study used nationwide data to assess the extent of treatment costs for patients with hepatitis A and to analyze factors that affect treatment costs.
Methods
Claims data for patients with acute hepatitis A whose primary diagnosis was coded as B15 in the International Classification of Diseases 10 th edition were extracted and analyzed from National Health Insurance (NHI) and Medical Aid Program during the 5-year period from January 1, 2004 to December 31, 2008. The collected data included only treatment costs covered by the NHI or Medical Aid; however, the treatment costs for non-reimbursed items were excluded. These claims data include all inpatient and outpatient treatment activities covered under NHI or Medical Aid for each year. Because the NHI and Medical Aid systems cover all Korean citizens, these claims data include all utilization of medical institutions in Korea for the study period.
The Korean health insurance program, initiated in 1976 by the government, achieved universal health coverage in 1989. The multiple insurers were integrated into a single payer, National Health Insurance Corporation (NHIC) and the Health Insurance Review and Assessment Service was founded to review and assess medical claims in 2000. Under the NHI Act, all health care services, whether public or private, are mandatory NHI providers. The NHIC pays providers for the share of medical costs not borne directly by the patient, on the basis of a fee schedule. Most of providers submit claims data through the electronic data interchange (EDI) system (Korea Institute for Health and Social Affairs 2005).
The claims data were reorganized into a data set based on individual users. The same person could use medical service several times during the study period. Thus, we created the individual data set by combining multiple claims data during the study period. Treatment costs for the years 2004-2007 were adjusted to 2008 standards to account for increased annual health insurance fees. Additionally, the currency exchange rate in 2008 (1102.6 Korean won for US$1) was applied. Approval was obtained from the Institutional Review Board (IRB) of Eulji University with a waiver for informed consent. There are no identified risks to the subjects of this study given that claims data are analyzed anonymously.
Socio-demographic variables included gender, age, residence area (classified by wide-area administrative district and urban and rural area), and insurance type (NHI for self-employed, NHI for industrial workers, and Medical Aid). Another category of individual-level variables related to medical services included complications (hepatic coma or hepatic failure), treatment start date, and treatment duration. Those who received inpatient care on more than one occasion were defined as inpatients regardless of their utilization of outpatient care, whereas patients who only utilized outpatient care without any inpatient care were defined as outpatients. The characteristics of the medical institutions included location, medical institution type (clinic, hospital, general hospital, or tertiary hospital), number of hospital beds, and whether the medical institution was a university hospital.
The total treatment costs for patients with hepatitis A and the average treatment costs per patient were calculated. Significant differences in treatment costs due to patient characteristics and medical institutions were assessed using t-tests and an analysis of variance. A stepwise multiple regression analysis was performed to analyze the effect of patient characteristics and medical institutions on treatment costs. All analyses were conducted using PC-SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA).
Results

General subject characteristics
In total, 72,921 patients received treatment for hepatitis A from January 1, 2004 until December 31, 2008. Among them, 38,826 received inpatient treatment, whereas 34,095 received only outpatient treatment. The gender distribution was 41,249 males (56.6%) and 31,675 females (43.4%). The average age of all patients was 34.7 years. The most commonly infected group was 30-39 (20,065 patients; 35.7%). The 20-49 year age group, which is a key productive group, accounted for 76.5% of all patients. The Seoul metropolitan area (Seoul city, Gyeonggi province, and Incheon city) accounted for 70% of the cases. The most common insurance type was that of industrial workers, with 64.7%. Only a small minority (1.7%) of all subjects were patients with complications. The number of patients with hepatitis A increased 4.1 times, from 7,439 patients in 2004 to 30,799 patients in 2008. In 2008, the number more than doubled compared to the previous year. The average treatment duration per inpatient was 12.9 days, whereas it was 2.7 days for outpatients. (Table 1) .
Treatment costs for patients with hepatitis A Total treatment costs:
The total treatment costs incurred by patients with hepatitis A during the 5 years (2004) (2005) (2006) (2007) (2008) were $47,902,086. During the study period, total treatment costs increased 7.7 times, from $3, 050,791 in 2004 to $23,450,740 in 2008. Costs of hospitalization during the study period increased 8.6 times, whereas physician visit costs increased 2.6 times. The ratio of inpatients to outpatients changed from 36:64 in 2004 to 61:39 in 2008. (Table 2) . (Table 3) .
Treatment costs by patient characteristics: Males had significantly higher average treatment cost per patient regardless of whether they were inpatients or outpatients. Patients 60 years of age or older had the highest treatment costs for both inpatients and outpatients, whereas the lowest treatment costs for inpatients were for under 10 years old, and the lowest treatment costs for outpatients were for the 20-29 year age group. Significant differences were observed between wide-area administrative districts for both inpatients and outpatients. No significant difference was observed for treatment costs among inpatients with regard to urban or rural classification, but rural area residents had significantly higher treatment costs among outpatients. Insurance type also had an effect; the treatment costs for Medical Aid beneficiaries were highest for both inpatients and outpatients. Severe type patients had higher treatment costs than patients without complications for both inpatients and outpatients. (Table 4) .
Treatment costs by hospital characteristics:
A comparison of treatment costs by characteristics of medical institutions showed that tertiary hospitals had the highest treatment costs, whereas clinics had the lowest treatment costs among medical facility types for both inpatients and outpatients. The largest hospitals with over 800 beds had the highest treatment costs, whereas the smallest hospitals, those with less than 100 beds, had the lowest treatment costs. An additional analysis of reclassifying higher hospital levels into university hospitals and non-university hospitals made it clear that university hospitals were associated with significantly higher treatment costs than non-university hospitals for both inpatients and outpatients. Significant differences were observed in the treatment costs for both types of patients according to hospital location, as classified by wide-area administrative district. (Table 5 ).
Factors affecting treatment costs per patient
The inpatient factors showed that treatment costs were significantly higher for females, older patients, and those with complications. Industrial workers with NHI had significantly lower treatment costs than Medical Aid beneficiaries. Compared to Seoul, the Jeju area was associated with significantly higher costs, whereas Gyeonggi, Incheon, and Kyeongsang showed significantly lower costs. Treatment costs were significantly related with the number of hospital beds. Analysis by treatment year showed that treatment costs in 2006, 2007, and 2008 were significantly higher compared to those in 2004. Among inpatients, the most influential factor on treatment costs was treatment duration, with a very high explanatory power of 46.3%.
The outpatient factors showed that treatment costs were significantly lower for females than males, whereas treatment costs were significantly higher as patient age increased. Industrial workers with NHI had significantly lower treatment costs than Medical Aid beneficiaries. When compared to Seoul, but excluding Gyeonggi and Incheon, residence areas had significantly higher treatment costs. Treatment costs significantly increased as the number of hospital beds at medical institutions increased. (Table 6 ).
Discussion
In this study, the number of patients treated for hepatitis A at medical institutions was 7,439 in 2004 and 30,799 in 2008, which was an increase of more than four times over 4 years. These patient numbers are much larger than those reported to the KCDC during the same period. The KCDC sentinel surveillance system for hepatitis A counted only the reports of symptomatic patients who are positive for IgM anti-HAV test from the designated medical institutions. So, the number of reports was less than the number from all medical institutions. From 2011, the hepatitis A was changed into the Class I legally designated communicable disease, and all medical institutions should report. The official statistics of hepatitis A from KCDC would significantly increase. However, in order to determine the exact status, it is necessary to improve the report rate by medical institutions or alternatively analyze the claims data used on this study.
Until the mid-1990s, hepatitis A did not draw much attention in Korea, because it was a rarely occurring infectious disease among adults. However, the number of symptomatic patients increased suddenly after the mid-2000s. As for the cause of this increase in the number of symptomatic patients, studies suggested that since economic development and improved sanitary conditions changed the epidemiology of hepatitis A in the country, there was a gradual increase in adolescents and adults without protective antibody against HAV Lee et al. 2008; Youn 2008; Lee et al. 2011 ).
The total costs for medical treatment of patients with hepatitis A from 2004 to 2008 were $47,902,087. Total treatment costs have increased 7.7 times, from $3, 050,791 in 2004 to $23,450,740 in 2008 . The share of treatment costs for hepatitis A of the total treatment costs paid by NHI was 0.2% in 2008. However, considering that the scale of expenses associated with the disease is growing rapidly and social management expenses other than medical expenses are necessary to prevent the occurrence of a wider epidemic, hepatitis A should not be treated lightly.
During the study period, physician visit costs increased 2.6 times, whereas hospitalization costs increased 8.6 times; hospitalization costs grew at a significantly higher rate. The ratio of inpatients to outpatients per year changed from 36:64 in 2004 to 61:39 in 2008; this illustrates a trend of continuous increase in the proportion of patients requiring inpatient care. The increase in patient age and their deteriorating condition has been used as an explanation for the increase in the number of inpatients (Kang et al. 2007; Kwon et al. 2008) . Average cost per hospital stay also increased.
Hospitalization costs accounted for 91.4% of total treatment costs, a higher percentage than that found in previous studies (61-84%) (Lucioni et al. 1998; Bownds et al. 2003; Sansom et al. 2003) . Thus, attention must be paid to the fact that recent service utilization of patients with hepatitis A has centered on inpatient care and that total treatment costs are increasing due to the increase in hospitalization costs. We should also note that subsequent economic and social losses will continue to worsen without a rapid and appropriate response to hepatitis A.
Although studies from other countries have analyzed treatment costs associated with hepatitis A, it is difficult to find a study targeting an entire population. For example, almost no studies of the total US burden for treatment costs due to hepatitis A are available. Hadler (1991) suggested that if 75,800 people are infected each year and 11,400 people receive hospital care, the annual national cost including treatment costs and work loss will be $200 million. Berge (ArteagaRodríguez et al. 2010) . The univariate analysis of average treatment costs by demographic characteristics indicated that treatment costs for males were significantly higher than those for females in both inpatients and outpatients. Furthermore, patients over the age of 60 years had the highest treatment costs. However, in the present multivariate analysis, gender affected treatment costs for inpatients differently. Previous study has reported that costs associated with patients with hepatitis A do not differ by gender and that the costs increase with increasing age (Jang et al. 2009 ). Further study related to the effects of patient demographic characteristics on treatment costs seems to be necessary. The average treatment costs for patients with hepatitis A by residence area also differed significantly. More research is necessary to examine whether the difference in treatment costs by location is a result of differences in health conditions of residents in different areas or a result of differences in medical service utilization, including differences in the characteristics and accessibility of an area's medical service system.
In the multivariate analysis, gender, age, insurance type, presence of complications, residence area, duration of treatment, number of hospital beds, and treatment year had a significant effect on treatment costs per patient with hepatitis A. In particular, treatment duration was identified with very high explanatory power. The average length of stay (LOS) was 10.2 days, which is longer than 4 days (mean) in the US, 4 days (median) in Canada, 6.8 days (mean) and 5 days (median) in Spain, and 9.5 days in Germany (CDC 1999; Diel and Rappenhoner 2000; Canueal et al. 2007; Arteaga et al. 2009; Arteaga-Rodríguez et al. 2010 ). Korean patients with hepatitis A may be more severe, and the LOS was longer. But it is not clear. In 2007, the average LOS of hospital inpatients for all diseases was 10.6 days and it was much longer than the average LOS -6.6 days -in OECD countries (OECD 2011) . It showed that the bed utilization of acute care was inefficient: Hospitals provide not only acute care services but also long term care services. Improper hospital stays not only decrease hospital profitability but also increase total treatment costs. The proportion of hospitalization costs of the overall treatment costs for patients with hepatitis A in Korea is large, and the average LOS for inpatients is long. Therefore, efforts to maintain treatment costs at appropriate levels through a reasonable management of treatment duration using standardized treatments are necessary. In addition, the difference in treatment costs by size of hospital indicated that selecting an appropriate medical facility for the patient's condition and specific needs is essential for managing treatment costs.
The hepatitis A can be prevented by vaccine, and it is necessary to consider not only the control of treatment costs but also the application of the vaccine. The HAV vaccine is considered to be very safe and there are few reports of serious adverse events (Craig and Schaffner 2004) . As not routine childhood vaccination but selective vaccination, the HAV vaccine is recommended for the all childhoods below 16 years old and high risk group of 20's and 30's in Korea (You 2010) . Two conventional doses of HAV vaccine in Korea cost about US$100, and the price is considerably expensive (Park 2009 ). However, the number of patients with hepatitis A and treatment costs of hepatitis A has been growing rapidly. So, it is necessary to make national policy to reduce the numbers in quick time. The standards of vaccination should be established based on the cost-effective analysis of vaccines and Korean situations.
Due to data limitations, only direct medical costs were analyzed in this study. In particular, only the treatment costs reimbursed by NHI and Medical Aid were analyzed; non-reimbursed treatment costs were not considered. However, because the main methods for treating acute hepatitis A are rest, a balanced diet, and adequate fluid supply rather than specific medications (Park 2009 ), we estimate non-reimbursed treatment costs to be small. If more sociodemographic factors are considered and medical service utilization aspects are analyzed specifically, more valuable basic data can be generated in the future. The complication of extra-hepatic manifestation such as acute renal failure was not analyzed in detail because there was limitation that the claim data did not have sufficient clinical information. Therefore, future research should be conducted by considering more clinical information of hepatitis A patients.
In conclusion, the results of this study confirm that the medical service utilization of patients with hepatitis A in Korea is rapidly growing and the hospitalization-focused treatment practice is a major factor associated with the rapid increase in treatment costs. Appropriate policies should be promptly developed to control treatment costs and economic burden of acute hepatitis A infections. The significance of this study is that it is the first to analyze the extent of treatment costs and the factors that affect treatment costs for all patients with hepatitis A in Korea.
